%0 Journal Article
%A Ribera, Jordi
%A Granada, Isabel
%A Morgades, Mireia
%A González, Teresa
%A Ciudad, Juana
%A Such, Esperanza
%A Calasanz, María-José
%A Mercadal, Santiago
%A Coll, Rosa
%A González-Campos, José
%A Tormo, Mar
%A García-Cadenas, Irene
%A Gil, Cristina
%A Cervera, Marta
%A Barba, Pere
%A Costa, Dolors
%A Ayala, Rosa
%A Bermúdez, Arancha
%A Orfao, Alberto
%A Ribera, Josep-Maria
%A Programa para el Tratamiento de Hemopatias Malignas (PETHEMA) Group (Spanish Society of Hematology, SEHH)
%T Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.
%D 2021
%U http://hdl.handle.net/10668/18532
%X The prognosis of t(1;19)(q23;p13)/transcription factor 3-pre-B-cell leukaemia homeobox 1 (TCF3-PBX1) in adolescent and adult patients with acute lymphoblastic leukaemia (ALL) treated with measurable residual disease (MRD)-oriented trials remains controversial. In the present study, we analysed the outcome of adolescent and adult patients with t(1;19)(q23;p13) enrolled in paediatric-inspired trials. The patients with TCF3-PBX1 showed similar MRD clearance and did not have different survival compared with other B-cell precursor ALL patients. However, patients with TCF3-PBX1 had a significantly higher cumulative incidence of relapse, especially among patients aged ≥35 years carrying additional cytogenetic alterations. These patients might benefit from additional/intensified therapy (e.g. immunotherapy in first complete remission with or without subsequent haematopoietic stem cell transplantation).
%K acute lymphoblastic leukaemia
%K adults
%K cytogenetic alterations
%K prognosis
%K t(1;19)(q23;p13)/TCF3-PBX1
%~